DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Thalassemia - Pipeline Review, H2 2016" report to their offering.
Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.
Thalassemia pipeline therapeutics constitutes close to 36 molecules. Out of which approximately 32 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 6, 16 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.
Thalassemia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Thalassemia Overview
- Therapeutics Development
- Pipeline Products for Thalassemia - Overview
- Pipeline Products for Thalassemia - Comparative Analysis
- Thalassemia - Therapeutics under Development by Companies
- Thalassemia - Therapeutics under Investigation by Universities/Institutes
- Thalassemia Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Thalassemia - Products under Development by Companies
- Thalassemia - Products under Investigation by Universities/Institutes
- Thalassemia - Companies Involved in Therapeutics Development
- Acceleron Pharma, Inc.
- Acetylon Pharmaceuticals, Inc.
- Acino International AG
- Agios Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Bellicum Pharmaceuticals, Inc.
- Bluebird bio, Inc.
- Editas Medicine, Inc.
- Emmaus Medical, Inc.
- Errant Gene Therapeutics, LLC
- Gamida Cell Ltd.
- Gilead Sciences, Inc.
- Incyte Corporation
- Ionis Pharmaceuticals, Inc.
- IRBM Science Park SpA
- Johnson & Johnson
- Kiadis Pharma N.V.
- La Jolla Pharmaceutical Company
- Merck & Co., Inc.
- Pfizer Inc.
- PharmaEssentia Corporation
- Sangamo BioSciences, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/rkrwgm/thalassemia
